$NDRA
ENDRA Life Sciences Inc.
CIK:0001681682|SEC Filings
Condensed Consolidated Statement of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Operating Expenses | ||||
| Research and development | $ 233,665 | $ 381,061 | $ 1,010,075 | $ 909,746 |
| Sales and marketing | 5,813 | 68,834 | 10,091 | 137,825 |
| General and administrative | 1,243,778 | 851,195 | 2,636,838 | 1,722,801 |
| Total operating expenses | 1,483,256 | 1,301,090 | 3,657,004 | 2,770,372 |
| Operating loss | (1,483,256) | (1,301,090) | (3,657,004) | (2,770,372) |
| Other Income (Expenses) | ||||
| Other income (expense) | (45) | 13,066 | 306 | 37,456 |
| Digital asset staking compensation | 9,700 | 20,760 | ||
| Unrealized gain on change in fair value of digital assets | 1,290,892 | 2,029,068 | ||
| Realized gain on change in fair value of digital assets | 409,355 | 530,940 | ||
| Changes in fair value of warrant liability | (66,702) | 62,112 | (75,559) | 470,674 |
| Total other income | 1,643,200 | 75,178 | 2,505,515 | 508,130 |
| Income/(loss) from operations before income taxes | 159,944 | (1,225,912) | (1,151,489) | (2,262,242) |
| Provision for income taxes | ||||
| Net Income (Loss) | $ 159,944 | $ (1,225,912) | $ (1,151,489) | $ (2,262,242) |
| Net income (loss) per share – basic (in Dollars per share) | $ 0.12 | $ (1.71) | $ (0.91) | $ (3.55) |
| Net income (loss) per share – diluted (in Dollars per share) | $ 0.06 | $ (1.71) | $ (0.91) | $ (3.55) |
| Weighted average common shares – basic (in Shares) | 1,324,046 | 717,107 | 1,262,040 | 637,362 |
| Weighted average common shares – diluted (in Shares) | 2,475,261 | 717,107 | 1,262,040 | 637,362 |